Cite
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy.
MLA
Jin, Jin, et al. “MIP3α as an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR-T Cell Cocktail Therapy.” Cancer Immunology, Immunotherapy, vol. 72, no. 7, July 2023, pp. 2245–56. EBSCOhost, https://doi.org/10.1007/s00262-023-03418-2.
APA
Jin, J., Liu, T., Cheng, J., Meng, J., Wang, N., Huang, L., Zhou, X., Chen, L., Luo, H., & Zhou, J. (2023). MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy. Cancer Immunology, Immunotherapy, 72(7), 2245–2256. https://doi.org/10.1007/s00262-023-03418-2
Chicago
Jin, Jin, Tianjiao Liu, Jiali Cheng, Jiao Meng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, and Jianfeng Zhou. 2023. “MIP3α as an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR-T Cell Cocktail Therapy.” Cancer Immunology, Immunotherapy 72 (7): 2245–56. doi:10.1007/s00262-023-03418-2.